Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype

BACKGROUND: Recent studies have suggested that the Src inhibitor dasatinib preferentially inhibits the growth of breast cancer cells of the basal-like subtype. To clarify this finding and further investigate combined antitumor effects of dasatinib with cytotoxic agents, a panel of breast cancer cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurebayashi, Junichi, Kanomata, Naoki, Moriya, Takuya, Kozuka, Yuji, Watanabe, Mika, Sonoo, Hiroshi
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967550/
https://www.ncbi.nlm.nih.gov/pubmed/20959018
http://dx.doi.org/10.1186/1471-2407-10-568

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967550/
https://www.ncbi.nlm.nih.gov/pubmed/20959018
http://dx.doi.org/10.1186/1471-2407-10-568

Ejemplares similares